Difference between revisions of "Siltuximab (Sylvant)"
m (PeterYang moved page Siltuximab (CNTO 328) to Siltuximab (Sylvant): brand name, FDA approval) |
(FDA approval) |
||
| Line 1: | Line 1: | ||
| + | ==General information== | ||
| + | Class/mechanism: Human-mouse chimeric monoclonal antibody which binds interleukin-6 (IL-6). Siltuximab prevents IL-6 from binding to soluble and membrane-bound IL-6 receptors. Blocking IL-6 activity interferes with its processes such immunoglobulin secretion. Systemic manifestations in patients with multicentric Castleman’s disease (MCD) has been associated with overproduction of IL-6.<ref name=insert>[http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf Siltuximab (Sylvant) package insert]</ref><ref>[[Media:Siltuximab.pdf | Siltuximab (Sylvant) package insert (locally hosted backup)]]</ref><ref>[http://www.sylvant.com/ Sylvant manufacturer's website]</ref> | ||
| + | <br>Route: IV | ||
| + | <br>Extravasation: no information | ||
| + | |||
| + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Castleman’s disease]] | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
| + | |||
| + | ==Patient drug information== | ||
| + | *[http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf#page=16 Siltuximab (Sylvant) package insert PDF pages 16-17]<ref name="insert"></ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *4/23/2014: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394522.htm FDA approved] "for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative." | ||
| + | |||
| + | ==Also known as== | ||
| + | CNTO 328. | ||
| + | |||
| + | ==References== | ||
| + | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Antibody medications]] | ||
| + | [[Category:IL-6 inhibitors]] | ||
| + | [[Category:Castleman’s disease medications]] | ||
| + | [[Category:Drugs FDA approved in 2014]] | ||
Revision as of 01:20, 24 April 2014
General information
Class/mechanism: Human-mouse chimeric monoclonal antibody which binds interleukin-6 (IL-6). Siltuximab prevents IL-6 from binding to soluble and membrane-bound IL-6 receptors. Blocking IL-6 activity interferes with its processes such immunoglobulin secretion. Systemic manifestations in patients with multicentric Castleman’s disease (MCD) has been associated with overproduction of IL-6.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 4/23/2014: FDA approved "for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative."
Also known as
CNTO 328.